fluticasone/salmeterol

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

AsthmaChronic Obstructive Pulmonary Disease

1050 competitors in Asthma

#DrugCompanyPhaseTrials

1

fluticasone/salmeterol

Novartis

Approved

42

Singulair

AstraZeneca

Preclinical

173

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

304

Celexa

AbbVie

Preclinical

15

Atrovent

Boehringer Ingelheim

Preclinical

56

Aciphex

Akero Therapeutics

Preclinical

27

Decadron

QQuince Therapeutics S.p.A.

Preclinical

18

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

19

Paracetamol

GSK

Preclinical

110

Blood Withdrawn

Emergent BioSolutions

Preclinical

1Show 10 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Salmeterol5 trials

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Withdrawn·Novartis·Phase 3·NCT01860066

Effect of Tiotropium Plus Salmeterol vs. Fluticasone/Salmeterol on Static Lung Volumes and Exercise Endurance in COPD

Completed·Boehringer Ingelheim·Phase 4·NCT00530842·344 enrolled

A 12 Week Study of QVA149 Compared to Fluticasone/Salmeterol (Advair) for Treatment of COPD

Withdrawn·Novartis·Phase 3·NCT01834885

Show 2 more trials

Small Airway Function of Fluticasone/Formoterol (Flutiform®) and Fluticasone/Salmeterol

Terminated·MMundipharma Korea Ltd·Phase 4·NCT02491970·15 enrolled

Interactive Acute Smooth Muscle Effects of Salmeterol and Fluticasone in the Airway

Completed·UUniversity of Miami·N/A·NCT01231230·14 enrolled

Asthma4 trials

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

Completed·GSK·Phase 3·NCT02924688·2,436 enrolled

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma

Completed·UUniversity of Dundee·Phase 4·NCT00830505·38 enrolled

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

Recruiting·GGelb, Arthur F., M.D.··NCT00576069·60 enrolled

Show 1 more trial

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Active, not recruiting·Sanofi·Phase 2·NCT06676319·556 enrolled

Chronic Obstructive Pulmonary Disease2 trials

QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Completed·Novartis·Phase 3·NCT01315249·523 enrolled

Effect on Adrenal Function of Budesonide Versus Fluticasone in Chronic Obstructive Pulmonary Disease (COPD)

Completed·HHull University Teaching Hospitals NHS Trust·Phase 4·NCT01186653·22 enrolled

Efficacy and Safety1 trial

A 26-week Treatment Randomized, Double-blind, Double Dummy Study to Assess the Efficacy and Safety of QVA149

Completed·Novartis·Phase 3·NCT01709903·744 enrolled

Dendritic Cell1 trial

Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers

Completed·UUniversity of Rostock·Phase 1·NCT00908362·45 enrolled

1 more indication

Unspecified3 trials

Symbicort Onset of Action 1

Completed·AstraZeneca·Phase 3·NCT00646620·48 enrolled

Atlantis Symbicort

Completed·AstraZeneca·Phase 3·NCT00646594·1,200 enrolled

Symbicort Onset of Action 2

Completed·AstraZeneca·Phase 3·NCT00646009·48 enrolled

Details

Drug Info

Related News